SCHEMBL2687827

SCHEMBL2687827

CCOC(=O)N1CCC(n2c(C)nc3cc(-c4nc5ccccc5o4)ccc32)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.46
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ PIK3CA P42336 1/20 0.45
▸ MTOR P42345 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ PKM P14618 3/20 0.44
▸ USP2 O75604 2/20 0.44
▸ MAPK1 P28482 4/20 0.44
▸ MET P08581 2/20 0.43
▸ MAPT P10636 3/20 0.42
▸ FPR2 P25090 1/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ HPGD P15428 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10219571 0.90 CCR5 (0.46) LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1
SCHEMBL2688265 0.84 ALDH1A1 (0.47) LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1
SCHEMBL2687957 0.82 EP300 (0.48) LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1
SCHEMBL2687060 0.82 KDM4E (0.54) LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1
SCHEMBL2686439 0.81 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1KDM4EL3MBTL1GAA
SCHEMBL2688684 0.81 MET (0.44) SMN1; SMN2ALDH1A1KDM4EL3MBTL1HTT
SCHEMBL16015419 0.81 ALDH1A1 (0.44) LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1
SCHEMBL2686300 0.80 ALDH1A1 (0.46) LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1
SCHEMBL2688665 0.79 USP2 (0.42) LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1
SCHEMBL15693817 0.78 HSD17B10 (0.41) LMNASMN1; SMN2ALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
EP-2436683-B1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL CO (JP) 2014-05-14 — — EP disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 LMNA 1152/4885SMN1; SMN2 157/4885ALDH1A1 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback